Trial Profile

In patients with advanced solid tumours, is an autologous cancer vaccine (RGSH4K), safe and tolerable, and can a biologically active dose be identified?

Status: Discontinued

Phase of Trial: Phase I

Latest Information Update: 28 Aug 2018

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs RGSH4K (Primary) ; Freund's adjuvant; Streptavidin
Indications Solid tumours
Focus Adverse reactions; First in man
Acronyms ACTIVATE
Sponsors Regeneus ltd

Most Recent Events

23 Aug 2018 Status changed from recruiting to discontinued.
30 Jul 2018 According to a Regeneus ltd media release, the primary endpoint of safety and tolerability has been met in this trial. Professor Stephen Clarke and Associate Professor Nick Pavlakis are the principal investigators of this trial.
19 Jun 2015 New trial record

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com